Results 61 to 70 of about 7,117 (221)

Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome [PDF]

, 2023
Hemolytic-uremic syndrome (HUS) can occur as a complication of an infection with Shiga-toxin (Stx)-producing Escherichia coli . Patients typically present with acute kidney injury, microangiopathic hemolytic anemia and thrombocytopenia. There is evidence
Amann, K, Coldewey, SM, Daniel, C, Dennhardt, S, Gunzer, F, Krieg, N, Kroeller, S, Thiemermann, C, Wissuwa, B   +8 more
core   +2 more sources

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL‐321

British Journal of Haematology, EarlyView.
Summary BRUIN CLL‐321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression‐free survival (PFS) compared to investigator's choice (IC) of ...
Shuhua Yi, Jiang Cao, Ru Feng, Keshu Zhou, Lihua Qiu, Fei Li, Hai Yan Yang, Hui Zhou, Wuhan Hui, Jie Cui, He Huang, Jiankun Zhu, Xiuhui Ye, Jeff Sharman, Lugui Qiu   +14 more
wiley   +1 more source

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

CPT: Pharmacometrics & Systems Pharmacology, 2019
Acalabrutinib, a selective, covalent Bruton tyrosine kinase inhibitor, is a CYP3A substrate and weak CYP3A/CYP2C8 inhibitor. A physiologically‐based pharmacokinetic (PBPK) model was developed for acalabrutinib and its active metabolite ACP‐5862 to ...
Diansong Zhou, Terry Podoll, Yan Xu, Ganesh Moorthy, Karthick Vishwanathan, Joseph Ware, J. Greg Slatter, Nidal Al‐Huniti   +7 more
doaj   +1 more source

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes

Frontiers in Cell and Developmental Biology, 2021
The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also revolutionized the treatment options for other B cell malignancies ...
Sining Zhu, Sining Zhu, Samantha Gokhale, Samantha Gokhale, Jaeyong Jung, Jaeyong Jung, Eris Spirollari, Jemmie Tsai, Johann Arceo, Ben Wang Wu, Eton Victor, Ping Xie, Ping Xie   +12 more
doaj   +1 more source

Bruton’s tyrosine kinase inhibitors impair FcγRIIa-mediated platelet responses to bacteria in chronic lymphocytic leukaemia [PDF]

, 2021
Ibrutinib is highly effective in the treatment of chronic lymphocytic leukaemia (CLL), disrupting B cell receptor signalling through the inhibition of Bruton’s tyrosine kinase (Btk).
Naylor-Adamson, Leigh
core   +1 more source

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study [PDF]

, 2020
Background: Chemoimmunotherapy is typically the standard of care for patients with Waldenström macroglobulinemia; however, infectious and hematologic toxic effects are problematic.
Aurran-Schleinitz T., Chen D. -Y., Cheson B. D., D'Sa S., Forconi F., Frigault M. M., Furman R. R., Greenwald D., Hamdy A., Iyengar S., Izumi R., Kastritis E., Kersten M. J., Kothari J., Lee S. K., McCarthy H., Minnema M. C., Mittag D., Owen R. G., Patel P., Rule S., Thomas S. K., Tournilhac O., Walter H., Wei H., Zinzani P. L.   +25 more
core   +1 more source

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.
ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease [PDF]

, 2020
The proteasome is the central component of the main cellular protein degradation pathway. During the past four decades, the critical function of the proteasome in numerous physiological processes has been revealed, and proteasome activity has been linked
Li, Jing, Sherman, David J.
core  

Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

Pharmaceutics, 2021
Calquence® (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated ...
Deanna M. Mudie, Aaron M. Stewart, Jesus A. Rosales, Nishant Biswas, Molly S. Adam, Adam Smith, Christopher D. Craig, Michael M. Morgen, David T. Vodak   +8 more
doaj   +1 more source

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial. [PDF]

Nat Commun
This phase II trial aims to determine the efficacy and safety of frontline acalabrutinib, lenalidomide and rituximab for patients with advanced stage follicular lymphoma (FL) and high tumor burden.
Strati P, Feng L, Westin JR, Nair R, Fayad LE, Rodriguez MA, Chihara D, Malpica L, Henderson J, Gallardo M, Rivera M, Wang I, Bolshakova A, Radko A, Kurtz D, Alig SK, Flowers CR, Alizadeh AA, Neelapu SS.   +18 more
europepmc   +2 more sources